Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD465 in Adults with ADHD
NCT00202605Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2005
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHP465 mixed amphetamine salts in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Sep 2005; status: completed.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00202605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202605.